The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Open accessAbstract
Immune checkpoint blockade therapy targets T cell-negative costimulatory molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1). Combination anti–CTLA-4 and anti–PD-1 blockade therapy has enhanced efficacy, but it remains unclear through what mechanisms such effects are mediated. A critical question is whether combination therapy targets and modulates the same T cell populations as monotherapies. Using a mass cytometry-based systems approach, we comprehensively profiled the response of T cell populations to monotherapy and combination anti–CTLA-4 plus anti–PD-1 therapy in syngeneic murine tumors and clinical samples. Most effects of monotherapies were additive in the context of combination therapy; however, multiple combination therapy-specific effects were observed. Highly phenotypically exhausted cluster of differentiation 8 (CD8) T cells expand in frequency following anti–PD-1 monotherapy but not combination therapy, while activated terminally differentiated effector CD8 T cells expand only following combination therapy. Combination therapy also led to further increased frequency of T helper type 1 (Th1)-like CD4 effector T cells even though anti–PD-1 monotherapy is not sufficient to do so. Mass cytometry analyses of peripheral blood from melanoma patients treated with immune checkpoint blockade therapies similarly revealed mostly additive effects on the frequencies of T cell subsets along with unique modulation of terminally differentiated effector CD8 T cells by combination ipilimumab plus nivolumab therapy. Together, these findings indicate that dual blockade of CTLA-4 and PD-1 therapy is sufficient to induce unique cellular responses compared with either monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3. Mass cytometry analysis of peripheral blood from patients treated with checkpoint blockade reveals treatment-specific effects. (A) Frequency of Ki-67+ cells within PD-1− and PD-1+ fractions of CD8 T cells in peripheral blood from patients treated with checkpoint blockade therapies (anti–CTLA-4, ipilimumab [Ipi], anti–PD-1 monotherapy, and ipilimumab plus nivolumab [Ipi + Nivo]) and normal donors is displayed. *P < 0.05, 1-way ANOVA with Sidak’s multiple testing correction. n.s., not significant. (B) tSNE plot of T cells from peripheral blood from patients treated with checkpoint blockade therapies. The plot is color-coded by treatment. Equal numbers of events per treatment group are displayed. (C) tSNE plots of T cells from peripheral blood overlaid with the expression levels of CD4, CD8, and TBET as heat maps. (D) Frequency of CD8 T cell metaclusters identified in peripheral blood from normal donors and patients treated with monotherapy and combination checkpoint blockade therapy. *P < 0.05 Tukey’s 2-way ANOVA with multiple testing correction. The mean and SD are displayed for each frequency plot. ND, normal donor. (E) Frequency of CD4 effector T cell metaclusters identified in peripheral blood from normal donors and patients treated with monotherapy and combination checkpoint blockade therapy. *P < 0.05, Tukey’s 2-way ANOVA with multiple testing correction. (See also SI Appendix, Figs. S3 and S4.)](https://figures.cochat.ai/paper-figures/a174ac947ef644df9dac9cc94be3e0e5/combination-antictla-4-plus-antipd-1-checkpoint-blockade-utilizes-cellular-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Anti-CTLA-4 therapy has been somewhat effective in melanoma and several other cancers, and blockade of the PD-1/PD-L1 axis is now first-line therapy for various tumor types, particularly melanoma and non-small cell lung carcinoma, with their combination being superior at the expense of enhanced adverse effects359,360.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [360]
Experimental — accuracy not yet measuredIn the citing paper
“This is biologically plausible, given that we know that CICB has a distinct mechanism of action compared to anti-PD-1 monotherapy 48 and distinct baseline tumor immune microenvironment signatures 49 .”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [48]
In the citing paper
“Wei and colleagues20 have shown that combination therapy with CTLA-4 and PD-1 blockade mediates a switch from expansion of exhausted CD8+ T cells to expansion of activated effector CD8+ T cells.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [20]
In the citing paper
“Anti-CTLA-4 therapy has been somewhat effective in melanoma and several other cancers, and blockade of the PD-1/PD-L1 axis is now first-line therapy for various tumor types, particularly melanoma and non-small cell lung carcinoma, with their combination being superior at the expense of enhanced adverse effects359,360.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [360]
In the citing paper
“Anti-CTLA-4 therapy has been somewhat effective in melanoma and several other cancers, and blockade of the PD-1/PD-L1 axis is now first-line therapy for various tumor types, particularly melanoma and non-small cell lung carcinoma, with their combination being superior at the expense of enhanced adverse effects359,360.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [360]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Self-citationNivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Self-citationData-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis
Levine, J. H., Simonds, E. F., Bendall, S. C., Davis, K. L., Amir, E.-A. D., Tadmor, M. D., Litvin, O., Fienberg, H. G., Jager, A., Zunder, E. R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.047 · Cited by 2,303 · cited 6×
“To robustly identify tumor-infiltrating T cell populations across multiple replicate cohorts of mice, we utilized a PhenoGraphdriven metaclustering approach (Methods).”
MethodSelf-citation
Research works printed but not linked: 1
- M. Postow ., “Pooled 3-year overall survival data from phase II and phase III trials of nivolumab (NIVO) combined with ipilimumab (IPI) in advanced melanoma” in 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One, P. J. Romero, Ed. (Journal for ImmunoTherapy of Cancer, 2017), vol. 5, p. 86.
Cited by
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Cascone, T., William, W. N., Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M. C. B., Carter, B. W., Federico, L., Reuben, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01224-2 · Cited by 618
Self-citationImmunity, endothelial injury and complement-induced coagulopathy in COVID-19
Perico, L., Benigni, A., Casiraghi, F., Ng, L. F. P., Renia, L., & Remuzzi, G. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00357-4 · Cited by 607
Tekguc, M., Wing, J. B., Osaki, M., Long, J., & Sakaguchi, S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023739118 · Cited by 490
“Given the effectiveness of combination therapies with anti–CTLA-4 and anti–PD-1/PD-L1 for advanced stage cancers (50), our results imply that these combination therapies may strongly interfere with Treg-mediated immune suppression at both the priming and effector phases of T cell immune responses, thereby contributing…”
BackgroundLow-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
Herrera, F. G., Ronet, C., Ochoa de Olza, M., Barras, D., Crespo, I., Andreatta, M., Corria-Osorio, J., Spill, A., Benedetti, F., Genolet, R., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0003 · Cited by 451
“To attenuate macrophage suppression, we used aspirin, which prevents prostaglandin E 2 (PGE 2 )-mediated inhibition of DCs, attenuates Tregs and myeloid-derived suppressor cells (101, 102), and reduces endothelial FasL-mediated killing of homing effector T cells (51).”
Metadata
- Authors
- Wei, S. C., Anang, N.-A. A. S., Sharma, R., Andrews, M. C., Reuben, A., Levine, J. H., Cogdill, A. P., Mancuso, J. J., Wargo, J. A., Pe’er, D., & Allison, J. P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Columbia University (US)
- Computational and Systems Biology Program, Sloan Kettering Institute, New York, NY 10065;
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Allison, James P.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2019-10-21
- Volume
- 116
- Issue
- 45
- Pages
- 22699-22709
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6842624
- OpenAlex
- W2981443129
- Cited by
- 359
- References
- 55
- Citations by year
- 2026: 38 · 2025: 42 · 2024: 47 · 2023: 52 · 2022: 69 · 2021: 63 · 2020: 47 · 2019: 1
- FWCI
- 18.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Cancer Institute (P30CA16672)
- Cancer Prevention and Research Institute of Texas (R1203)
- National Health and Medical Research Council of Australia (#1148680)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint blockade, anti-CTLA-4, anti-PD-1, combination immunotherapy, T cell exhaustion, CD8+ T cells, melanoma, ipilimumab, nivolumab, mass cytometry, T cell subsets
- MeSH terms
- Animals, Immunotherapy, Neoplasms, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Mice, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. https://app.cochat.ai/papers/10.1073/pnas.1821218116
- The paper
- Wei, S. C., Anang, N.-A. A. S., Sharma, R., Andrews, M. C., Reuben, A., Levine, J. H., Cogdill, A. P., Mancuso, J. J., Wargo, J. A., Pe’er, D., & Allison, J. P. (2019). Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1821218116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.